Bacterial Vaginosis News and Research

RSS

Bacterial vaginosis (BV) is the name of a condition in women where the normal balance of bacteria in the vagina is disrupted and replaced by an overgrowth of certain bacteria. It is sometimes accompanied by discharge, odor, pain, itching, or burning.

New antibiotic combinations aim to prevent recurrent bacterial vaginosis

Researchers and clinicians from Monash University and Bayside Health's Melbourne Sexual Health Centre are trialing new combinations of antibiotics to treat persistent bacterial vaginosis (BV), following their landmark discovery that the condition is sexually transmissible.

30 Sep 2026

Computer models could design more effective probiotic supplements

Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, new University of Virginia School of Medicine research reveals.

18 Jun 2026

How a common gut bacterium may protect health

Akkermansia muciniphila's impact on immunity and pregnancy outcomes underscores its promise as a probiotic, with implications for infectious disease treatment.

4 May 2026

How do diet, smoking, alcohol, and stress reshape the female microbiome?

This review examines how modifiable lifestyle and environmental factors shape the female vaginal, gut, oral, and skin microbiomes, with diet, alcohol, smoking, obesity, stress, hygiene, physical activity, and sexual behaviours all linked to site-specific microbial shifts. It argues that understanding these patterns could help guide future female-focused prevention and intervention strategies.

30 Mar 2026

Study reveals how a promising bacterial therapy reduces recurrent bacterial vaginosis

A new study from the Kwon Lab at the Ragon Institute, published in Cell Host & Microbe, provides the most detailed picture yet of how a promising bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others.

27 Mar 2026

Vaginal microbiome may play key role in pregnancy health and preterm birth risk, researchers say

Researchers reviewed evidence linking the vaginal microbiome to pregnancy health and spontaneous preterm birth, highlighting how Lactobacillus-dominated communities help maintain immune balance and vaginal acidity. Dysbiosis and inflammatory signaling may contribute to preterm birth risk, while emerging microbiome-targeted therapies aim to restore protective microbial ecosystems.

15 Mar 2026

New analysis reveals hidden complexity in the vaginal microbiome

For decades, gynecological tests have relied on a simplified view of the vaginal microbiome, categorizing bacteria as either "good" or "bad."

6 Feb 2026

Pregnant individuals with inflammatory bowel disease show heightened vaginal inflammation

Pregnant individuals with inflammatory bowel disease (IBD) have higher levels of pro-inflammatory immune molecules, known as cytokines, in their vaginal mucosa than their healthy counterparts, according to a new study published January 14, 2026 in the open-access journal PLOS One by Ana Maldonado-Contreras of University of Massachusetts Chan Medical School, U.S., and colleagues.

14 Jan 2026

Powerful optical technique can analyze the biochemical fingerprints of vaginal fluid

Vaginal health is tightly linked to the balance of bacteria in the microbiome, especially certain species of Lactobacillus.

12 Aug 2025

Eating habits directly influence vaginal microbiome, research finds

A cross-sectional study of young Italian women found that higher intake of animal protein and alcohol is associated with vaginal microbiota dysbiosis, while linolenic acid (a plant-based omega-3) and dietary fiber support beneficial Lactobacillus communities.

7 Jul 2025

Vaginal microbiome fights back against stubborn BV infections

Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for personalized approaches to enhance efficacy.

3 Jul 2025

New PCR test offers hope for better treatment of bacterial vaginosis

Roughly one out of three women ages 14-49 in the United States develop a vaginal bacterial imbalance known as bacterial vaginosis (BV) during their lifetime.

28 Mar 2025

New STI impacts 1 in 3 women: Landmark study reveals men are the missing link

A landmark study reveals that bacterial vaginosis (BV), a condition affecting nearly a third of women worldwide and causing infertility, premature births and newborn deaths, is in fact a sexually transmitted infection (STI), paving the way for a revolution in how it is treated.

5 Mar 2025

Study highlights the need for more diversity in vaginal microbiome research

This study emphasizes the need for global equity in vaginal microbiome research, addressing health disparities and improving female health strategies worldwide.

14 Feb 2025

Global study reveals diversity in healthy vaginal microbiomes

Seeking to understand what constitutes a healthy vaginal microbiome, a global research collaboration that includes a Rutgers-New Brunswick scientist has reported a series of findings, including identifying which bacteria thwart vaginal disease and determining that microbiomes vary significantly across human populations.

11 Feb 2025

New study links cervicovaginal microbiome to increased risk of Chlamydia infections

The cervicovaginal microbiome's role in Chlamydia infections underscores the need for molecular classification to enhance prevention and treatment strategies.

17 Jan 2025

New research identifies key subtype of bacterial vaginosis that increases chlamydia risk

Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial infection.

16 Jan 2025

Case Western Reserve secures $1.5 million NIH grant to improve bacterial vaginosis treatments

Bacterial vaginosis (BV), the most prevalent condition affecting the female reproductive system in women aged 15 to 44, is linked to such serious health risks as preterm birth, gynecological malignancies and sexually transmitted diseases.

25 Nov 2024

Freya Biosciences secures new investment to develop microbial immunotherapies for bacterial vaginosis

Freya Biosciences (Freya or the Company), a transatlantic biotech company specializing in women's health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation (the foundation) with $1.4 million additional financing from current investor Export and Investment Fund of Denmark (EIFO).